A detailed history of Woodline Partners LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 3,478,440 shares of RCUS stock, worth $53.9 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
3,478,440
Previous 4,245,221 18.06%
Holding current value
$53.9 Million
Previous $64.7 Million 17.74%
% of portfolio
0.48%
Previous 0.65%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$13.69 - $18.01 $10.5 Million - $13.8 Million
-766,781 Reduced 18.06%
3,478,440 $53.2 Million
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $19.9 Million - $25.2 Million
1,361,564 Added 47.22%
4,245,221 $64.7 Million
Q1 2024

May 15, 2024

BUY
$14.83 - $20.18 $27.4 Million - $37.3 Million
1,846,375 Added 178.0%
2,883,657 $54.4 Million
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $13.9 Million - $18.6 Million
789,282 Added 318.26%
1,037,282 $18.6 Million
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $4.21 Million - $5.46 Million
248,000 New
248,000 $5.04 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $23.7 Million - $42.9 Million
1,201,150 New
1,201,150 $24.8 Million
Q2 2022

Aug 15, 2022

SELL
$17.23 - $37.73 $4.5 Million - $9.86 Million
-261,419 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$28.92 - $41.83 $41.8 Million - $60.4 Million
-1,445,006 Reduced 84.68%
261,419 $8.25 Million
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $229,450 - $354,412
7,312 Added 0.43%
1,706,425 $69.1 Million
Q3 2021

Nov 15, 2021

BUY
$26.93 - $37.68 $957,226 - $1.34 Million
35,545 Added 2.14%
1,699,113 $59.2 Million
Q2 2021

Aug 16, 2021

BUY
$22.75 - $35.77 $9.69 Million - $15.2 Million
425,838 Added 34.4%
1,663,568 $45.7 Million
Q1 2021

May 17, 2021

BUY
$26.16 - $41.39 $32.4 Million - $51.2 Million
1,237,730 New
1,237,730 $34.8 Million
Q2 2020

Aug 14, 2020

SELL
$13.97 - $36.56 $1.38 Million - $3.6 Million
-98,516 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$8.78 - $19.28 $864,970 - $1.9 Million
98,516 New
98,516 $1.37 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.12B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.